About Research at UPMC Hillman Cancer Center

UPMC Hillman Cancer Center (Hillman) is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center - one of only 52 in the U.S.

At UPMC Hillman Cancer Center, our researchers collaborate with our clinician-scientists to advance the most promising laboratory studies into novel clinical trials in order to provide patients with early access to new and innovative treatments.

The nationally and internationally renowned research at UPMC Hillman Cancer Center includes a range of disciplines, from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end-of-life care.

We are also dedicated to the education and training of the next generation of cancer researchers and physicians, as well as the ongoing recruitment of world-renowned scientists.

UPMC Hillman Cancer Center is the only NCI-designated Comprehensive Cancer Center in western Pennsylvania. We are dedicated to excellence for our patients, and we are working to make vast strides in the global effort to reduce the burden of cancer.

Research

Advancing our understanding of cancer through scientific discovery

Training

Preparing the next generation of researchers and clinicians

Community Outreach

Community Outreach

Educating the community on cancer prevention, treatment, and survivorship

Clinical Trials

Defining lifesaving approaches to prevent, diagnose, and treat cancer

Patients and Families

Learn about the conditions we treat, available therapies, and the UPMC Hillman Cancer Center difference

Robert Ferris

 

Director’s Message

Robert L. Ferris, MD, PhD

UPMC Hillman Cancer Center is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and the preeminent institution in western Pennsylvania for providing cancer care; conducting basic, translational, clinical, and population science research; and educating the next generation of cancer researchers and physicians.

We have more than 300 researchers across our programs, who are quickly advancing the latest research discoveries into pioneering therapies that can benefit the more than 130,000 patients seen each year throughout our integrated cancer care delivery network. Read more.